Diabetes Flashcards

0
Q

Sulfonylureas (secretagogues)

A

Increase insulin production by pancreas. Bind to Katp channel, Inhibit K efflux, depolarize, increase Ca, increase insulin release

glipizide (take on empty stomach), glimepiride, glyburide (not recommended cardio MI)

Contraindicated in liver/renal impairment

Weight gain, hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Alpha glucosidase (amylase) inhibitors

A

Slow starch and disaccharide absorption in the gut
Lower post-prandial peak

Acarbose, Glyset

If hypoglycemic give simple sugar (glucose/galactose)

Adverse: flatulence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Meglitinides

A

Bind to SUR1.More potent release of insulin from pancreas. Insulin suppresses hepatic glucose production

Nateglinide, repaglinide

May cause weight gain, hypoglycemia

Flexible, skip dose if skipped meal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Biguanide

Decrease all cause mortality, MI

A

Decrease glucose production in liver
Increase peripheral glucose uptake (Glut4) and activate AMPK (inhibit PEPCK glucose formation) decrease conversion of lactate to pyruvate

Increase fatty acid oxidation, less fatty liver, increase hepatic insulin sensitivity

Decrease intestinal glucose absorption

Metformin, take with largest meal
Weight loss, improves lipid profile
Adverse: diarrhea, VitB12 deficiency, lactic acidosis avoid: SCr >1.5
Cleared renally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Thiazolidinediones (TZD)

A

Increase uptake of sugar by muscle and fat cells (adipocytes)

PPARy ligands, increase adiponectin (good for insulin sensitivity)

Pioglitazone, rosiglitazone (more toxic on lipid profile)

Cause weight gain (adipose PPARy triglyceride synthesis from glucose)
And fluid retention (kidney PPARy), edema CHF, bone fracture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Proinsulin

A

Endogenous

Has C-peptide

T1DM lacks proinsulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Type 1 DM

A

No insulin to bind to receptor and stimulate glucose uptake or conversion into fatty acids

Goal preprandial 110
2 hour post prandial 140

Requires multiple insulin injections and

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Type 2 DM

Risk >45 African Latino Asian

A

Skeletal muscle and adipose tissue become insulin resistant

Decreased signaling capacity for the insulin receptor. Glut transporter 4 levels decrease

Not a CHD risk equivalent

Can have single insulin injection w/oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Insulin

Benefit of early addition

A

Inhibit PEPCK (rate limiting enzyme)

Bind to insulin receptor, glut4 transporter, glucose into glycogen, pyruvate, fatty acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Humalog

A

Reverses Lys and Pro (lispro)
Rapid acting

15 min before or at meal

Use rapid acting in insulin pump

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Novolog

A

Insulin aspart

Proline to aspartic acid

Rapid acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Apidra

A

insulin glulisine

Glutamic acid to lysine

Rapid acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Short acting insulin

A

Novolin R, Humulin R

IV insulin Recombinant direct hexamer to monomer (no dimer) faster absorption

Effect appears in 30 min
More weight gain, more glycemic highs and lows

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Intermediate acting

A

NPH Novolin N
NPH Humulin N

Effect appears in 2 hours

Less doses BID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Long acting

A

Insulin glargine (lantus) - precipitates at neutral pH. Glycine to asparagine

Insulin detemir (Levemir)

Long duration, designed to be peakless
Less weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Incretins/GLP-1

Pen formulations

A

Stimulate release of insulin during a meal before glucose levels rise

Exanatide (Byetta)

Potentiate glucose-mediated insulin secretion
Suppress postprandial glucagon release
Slow gastric emptying

Cause weight loss

Avoid if CrCl <30

16
Q

DPP4 inhibitor

A

DPP4 enzyme inactivates GLP-1

Inhibit DPP4

Sitagliptan (Januvia)

No weight gain
May increase heart failure

Do not combo w/ GLP

17
Q

HgbA1C < 9%

A

Metformin & lifestyle

Metformin lowers 2% A1C at best

Caution alcohol lowers blood sugar

18
Q

HgbA1C 9-10%

A

Metformin + 2nd agent

Sulphonylurea, TZD, DPP4inhibitor, GLP-1

19
Q

HgbA1C >10%

A

Metformin & insulin

Scr > 1.5 give insulin

20
Q

Sodium glucose transporter 2 inhibitor

A

Inhibit glucose reabsorption in proximal tubule and let glucose be released in the urine

Canigliflozin, dapagliflozin

Weight loss, lowers BP

Need GFR>60

Chronic urinary glucose excretion is benign

21
Q

Statin

A

Proves beneficial, regardless of LDL goal target, 30% change is ideal

High Beneficial if prior stroke (ASCVD)
40-75 w/diabetes
LDL >190
40-75 w/ASCVD risk >7.5%

High intensity: ator 80, rosu 20 for overt CVD

Caution myopathy in elderly >75
Can supplement VitD

22
Q

Blood pressure

A

Target is < 140/80

Target 120/80 long term renal disease

23
Q

Persistent albuminuria >30mg/day

Protein spills in urine

A

Initiate thiazides, ACE, ARB, or CCB

Thiazides, CCBs first line in blacks

Don’t combine ACE and ARB

Beta blockers are not first line anti hypertensive therapy

24
Weight loss
Decrease adipocytes, increase adiponectin, increase insulin sensitivity
25
Brain function
Blood glucose >40mg/dL
26
Blood glucose monitoring
Check glucose 2 hours after injecting
27
Insulin injections Use within 28 days Syringe requires dexterity Pens are easier, more expensive
Rotate injection site Inject to fat vs. muscle (faster uptake) Abdomen>arm>thigh> 0.5 U/kg/day 1/2 basal (glargine) 1/2 / 3 at each meal (lispro)
28
A1C to mg/dL
130mg/dL=6% 30mg/dL=1% Goal <8% if vascular complications General 7%, recently diagnosed Reduce microvascular, MI Every 1% increase increases CVD 18%
29
Mixed insulin
Higher % is NPH Lower % is short-acting Clear before cloudy (NPH) Never mix long acting
30
SMBG
Rapid: 2hours post prandial Short: before next meal or bed snack NPH: 12 hours after Long acting: before breakfast
31
Insulin pump
Good for those with dawn rise BG Recurrent hypoglycemia Lifestyle, busy Needs to monitor BG QID
32
Hypoglycemia
BG <70mg/dL Shaky, sweating, hunger 15g carb, 15 min check Glucagon if patient uncooperative or unconscious
33
Diabetic Keto Acidosis T1 and T2DM
INSULIN constant infusion Potassium supplement IV fluids
34
Hyperosmolar hyperglycemic state HHS or HONK no ketones
Mostly older T2DM Hypotonic fluids and low-dose insulin
35
Somogyi
Rebound hyperglycemia at night Decrease NPH dose at bedtime
36
ISensitivityF ICarbRatio
ISF = 1700/ total daily insulin doses 1 unit / mg/dL ICR= ISFx0.33